A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.
about
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potentPartial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptideOxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.A chemical perspective on the anthracycline antitumor antibioticsMonitoring subcellular biotransformation of N-L-leucyldoxorubicin by micellar electrokinetic capillary chromatography coupled to laser-induced fluorescence detection.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Protease-activated drug development.Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.Cytotoxic agents directed to peptide hormone receptors: defining the requirements for a successful drug.Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.Cancer nanomedicines: so many papers and so few drugs!Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generatorsIn vitro and in vivo evaluation of microparticulate drug delivery systems composed of macromolecular prodrugs.Serum proteins as drug carriers of anticancer agents: a review.Multifunctional dendritic polymers in nanomedicine: opportunities and challenges.Current understanding of synergistic interplay of chitosan nanoparticles and anticancer drugs: merits and challenges.Interfacing materials science and biology for drug carrier design.Endogenous lectins and drug targeting.The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer.New daunomycin-oligoarginine conjugates: synthesis, characterization, and effect on human leukemia and human hepatoma cells.Receptor mediated glycotargeting.Antibody-targeted drugs for the therapy of cancer.The mode of action of methotrexate-monoclonal antibody conjugates.Reversible Deactivation of Enzymes by Redox-Responsive Nanogel Carriers.
P2860
Q24309593-68D4431F-24BA-485D-AB2C-755C448C2A51Q33723283-849F4B73-E0BD-40E5-9636-018F262FD232Q34162875-FFA1F89F-AE5F-4173-B2A8-F5C4F1C236F7Q35035606-49D91811-6982-4F00-8FF1-BFC71BDF9FEAQ35103568-99805786-83EE-4CE5-A695-3C1D649AA434Q35459059-B69D5C6D-C237-4A1F-B433-D88B15ED3257Q35811508-337AEE79-DFF7-4166-8D92-0B7190075AA5Q36028818-A9AEC42C-7C6E-4A84-8B64-0CD1FA5B8F91Q36200153-7B62E0A2-D7C0-4229-9D5A-E3C17E4EB6B8Q36312379-F713187B-A551-4D99-83BF-AD2C0AFB4BEEQ36465829-8804D6B2-FF5A-4532-AC2D-CBE82355B11AQ36589023-85FCD9E9-ABF7-4370-B469-D362F6FDAFC1Q36643541-15BFF3D8-7FBE-401B-BFAF-E72F2D71DFB6Q36944649-5D072CA8-0174-4B82-8166-F85C3A1288FDQ37284600-146DDF72-9574-46D2-9B81-262F85431A64Q37537586-95340548-255B-439E-94B3-80A2213BC09BQ37967150-DCED821A-BBA8-49D6-BAAE-FB2BE5FE5106Q38362427-D4409268-078C-45DA-83E5-49D35154CEACQ38366527-D93A38E1-1FE7-48E9-A652-1D1BC085D35DQ39573069-7BB5E978-445F-4078-B5EC-E5E2E788214DQ39662817-2E87BD17-5975-48B1-8987-C2ECB3894AC7Q39838948-18F146E8-67CC-4DC7-8B05-570DE2B5E360Q40381389-065C886E-C3B6-404F-A630-C65A2A032132Q40563987-3A86B3D3-62C9-4C55-89F1-6EF774591C1DQ41913856-FD781405-9BD9-487B-AA45-2AE06898D988Q51506898-1D11FC13-9CCD-4D01-9049-9A5ACD30D7AB
P2860
A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh
1982年學術文章
@zh-hant
name
A covalent linkage between dau ...... in vitro and in vivo studies.
@ast
A covalent linkage between dau ...... in vitro and in vivo studies.
@en
type
label
A covalent linkage between dau ...... in vitro and in vivo studies.
@ast
A covalent linkage between dau ...... in vitro and in vivo studies.
@en
prefLabel
A covalent linkage between dau ...... in vitro and in vivo studies.
@ast
A covalent linkage between dau ...... in vitro and in vivo studies.
@en
P2093
P2860
P356
P1476
A covalent linkage between dau ...... in vitro and in vivo studies.
@en
P2093
Deprez-De Campeneere D
Masquelier M
P2860
P304
P356
10.1073/PNAS.79.2.626
P407
P577
1982-01-01T00:00:00Z